ITRMF (Iterum Therapeutics) Total Current Liabilities: $6.43 Mil (As of Sep. 2025)


What is Iterum Therapeutics Total Current Liabilities?

Iterum Therapeutics ITRMF +18.86% Total Current Liabilities is $6.43 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Iterum Therapeutics's total current liabilities for the quarter that ended in Sep. 2025 was $6.43

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Iterum Therapeutics Total Current Liabilities Related Terms

Iterum Therapeutics Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics Total Current Liabilities Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only 41.70 12.94 9.06 13.52 17.61

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.70 17.61 3.63 5.53 6.43

Iterum Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Iterum Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.902+14.463
+Other Current Liabilities+Current Deferred Liabilities
=0.24+0
=17.61

Iterum Therapeutics's Total Current Liabilities for the quarter that ended in Sep. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.817+0.281
+Other Current Liabilities+Current Deferred Liabilities
=0.332+0
=6.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $6.43 Mil mean?
Iterum Therapeutics (ITRMF) has a Total Current Liabilities of $6.43 Mil as of Sep. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Iterum Therapeutics and its competitors.
Is Iterum Therapeutics' Total Current Liabilities too high?
Iterum Therapeutics' current Total Current Liabilities is $6.43 Mil.
How does Iterum Therapeutics' Total Current Liabilities compare to ENSC and PPCB?
Iterum Therapeutics' Total Current Liabilities of $6.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Iterum Therapeutics and its competitors. Iterum Therapeutics's current Total Current Liabilities is $6.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Total Current Liabilities of $6.43 Mil. The current Total Current Liabilities is $6.43 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Total Current Liabilities is $6.43 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.